| Novo Nordisk HealthCare A/G Patent applications |
| Patent application number | Title | Published |
|---|
| 20120136298 | MIXING DEVICE WITH PISTON COUPLING ARRANGEMENT | 05-31-2012 |
| 20120115204 | VIRUS FILTRATION OF LIQUID FACTOR VII COMPOSITIONS - The present invention relates to a novel method for improving the viral safety of liquid Factor VII compositions, in particular those comprising active Factor VII polypeptides (a Factor VIIa polypeptide). | 05-10-2012 |
| 20120029464 | SYSTEM FOR RECONSTITUTION OF A POWDERED DRUG - A mixing system ( | 02-02-2012 |
| 20120003206 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITIONS OF FACTOR VII POLYPEPTIDES - The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a —C(═N—Z | 01-05-2012 |
| 20110177580 | Method of Controlling a Polypeptide Modification Reaction - The invention relates to a method of controlling a polypeptide modification reaction, in particular but not exclusively, a method of controlling the activation of human factor VII (FVII) to produce human factor VII(a) (FVII(a)). The invention also relates to polypeptides obtainable by the polypeptide modification reaction and to pharmaceutical compositions comprising said polypeptides. | 07-21-2011 |
| 20110081702 | Method for the Production of Proteins - The present invention relates to a process for the purification of a protease. | 04-07-2011 |
| 20110040073 | Covalent Factor VII-Tissue Factor Complex - The present invention relates to novel covalent complexes of a Factor VII polypeptide and a Tissue Factor polypeptide, in particular to such complexes which are functionally active and which have an enhanced proteolytic activity towards Factor X compared to the corresponding free Factor VII polypeptide as well as methods for production of these novel complexes. | 02-17-2011 |
| 20110014179 | USE OF FACTOR VIIA OR FACTOR VIIA EQUIVALENTS FOR PREVENTING OR ATTENUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) IN A SELECTED SUBPOPULATION OF ICH PATIENTS - The invention relates to a method for preventing or attenuating one or more complications of intracerebral haemorrhage (ICH), the method comprising: (i) selecting an ICH patient who exhibits one or more of the following characteristics: age≦70, baseline ICH volume≦60 mL, baseline IVH volume≦5 mL, and elapsed time since onset of symptoms of less than about 2.5 hours; and (ii) administering to said patient in need thereof an effective amount of a first coagulation agent comprising Factor VIIa or a Factor VIIa equivalent. | 01-20-2011 |
| 20100331773 | MEDICAL MIXING DEVICE - A drug storage and delivery device ( | 12-30-2010 |
| 20100297098 | Purification of Factor XIII Polypeptides from Biological Materials - The invention relates to a method for purifying a factor XIII polypeptide from a biological material, the method comprising subjecting the material to sequential chromatography on an anion-exchange matrix and a hydrophobic interaction matrix. | 11-25-2010 |
| 20100197597 | Coagulation Factor VII Polypeptides - The present invention relates to novel coagulation Factor VII polypeptides, polynucleotide constructs encoding such polypeptides, as well as vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment. | 08-05-2010 |
| 20100160236 | Method for Preventing Formation of Trisulfide Derivatives of Polypeptides - A method for reducing or substantially preventing formation of a trisulfide derivative of a polypeptide in a liquid medium containing the polypeptide ijn question comprises stripping the liquid medium with a gas, suitably a chemically unreactive gas such as nitrogen or argon. | 06-24-2010 |
| 20100158891 | Human Coagulation Factor VII Variants - The present invention encompasses isolated human coagulation Factor VII variants comprising a substitution of Phe in position 374 of SEQ ID NO 1 with another amino acid residue. | 06-24-2010 |
| 20100143326 | SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES - The invention relates to the use of a Factor VIIa-related polypeptide for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, in particular a bleeding episode, said medicament being for subcataneous or intramuscular administration. | 06-10-2010 |
| 20100136622 | Method for the Production of Proteins - The present invention relates to a process for the purification of a protease. | 06-03-2010 |
| 20100062983 | Use of Factor VIIa or Factor VIIa equivalents for treating late complications of trauma - The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing late complications in trauma patients. | 03-11-2010 |
| 20100056453 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides - The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a —C(═N—Z | 03-04-2010 |
| 20100041153 | Expression of Proteins in E. Coli - Plasmid comprising a DNA tag encoding a peptide tag of the sequence MX1(X 2X 3) n X 1 represents K or R; X 2 represents M, S or T; X 3 represents K or R; n represents an integer of 1 or larger; and wherein said DNA is operably-linked to a promoter sequence are provided. | 02-18-2010 |
| 20100029569 | Pharmaceutical Formulation - The invention relates to aqueous pharmaceutical formulations comprising human growth hormone, histidine, poloxamer, phenol, and mannitol. | 02-04-2010 |
| 20100028939 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest - This invention relates to novel compounds, methods for selective chemical conjugation of protractor molecules and the use thereof for diagnostic and/or therapeutic purposes. | 02-04-2010 |
| 20090281022 | Method for Producing Factor VII Glycoforms - The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions. | 11-12-2009 |
| 20090264366 | Transglutaminase Mediated Conjugation of Peptides - Methods for conjugating peptides are provided comprising i) reacting a peptide with a first compound comprising a functional group in the presence of a transglutaminase capable of incorporating said compound into the peptide to form a transaminated peptide, and ii) reacting said transaminated peptide with e.g. a functionalized polymer capable of reacting with the functional group incorporated in the peptide in the enzymatic reaction. | 10-22-2009 |
| 20090263866 | Industrial-scale Serum-free Production of Recombinant Factor VII in Mammalian Cells - The invention provides a method for industrial-scale production of FVII polypeptides in mammalian cell culture free of animal-derived components. | 10-22-2009 |
| 20090221800 | Method for the Production of Recombinant Proteins - The present invention relates to a process for the production of recombinant polypeptides in leukocytes. | 09-03-2009 |
| 20090191180 | Use of Factor VIIa Analogues with Increased Activity - The invention relates to methods for treatment of bleeding episodes in a subject with thrombocytopenia. | 07-30-2009 |
| 20090191179 | Use of factor VIIa analogues with increased activity - The invention relates to methods for the treatment of a severely bleeding subject. | 07-30-2009 |
| 20090176967 | Conjugation of FVII - New FVII polypeptides and FVIIa derivatives, uses of such peptides, and methods of producing these polypeptides and derivatives, are provided. | 07-09-2009 |
| 20090156481 | Use of Factor VIIa or Factor VIIa Equivalents for Preventing or Attenuating Haemorrhage Growth, and/or Oedema Generation Following Intracerebral Haemorrhage (ICH) in Patients Treated with Antiplatelet Therapy - The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing complications in ICH patients treated with antiplatelet therapy. | 06-18-2009 |
| 20090075331 | Industrial-scale serum-free production of recombinant proteins in mammalian cells - The invention relates to methods for cultivating mammalian cells and for producing recombinant proteins in large-scale cultures of such cells. The proteins are, e.g., Factor VII or Factor VII-related polypeptides. | 03-19-2009 |
| 20090055942 | Human Coagulation Factor VII Polypeptides - The present invention relates to novel human coagulation Factor Vila variants having substitutions of one or more amino acids at a position selected from the group consisting of position 172, 173, 175, 176, 177, 196, 197, 198, 199, 200, 203, 235, 237, 238, 239, 240, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 297, 299, 319, 320, 321, 327, 341, 363, 364, 365, 366, 367, 370, 373 corresponding to amino acid positions of SEQ ID NO:1 and wherein said Factor VII polypeptide exhibits increased resistance to inactivation by an endogenous inhibitor of said FVII polypeptide relative to wild-type human FVIIa. | 02-26-2009 |
| 20090053193 | Use of Factor VIIa for the Treatment of Burn Trauma - The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for treatment of burn trauma. | 02-26-2009 |
| 20090043080 | Purification of a Bulk of a Factor VII Polypeptide by Fractionated Elution from an Anion-Exchange Material - The present invention relates to the purification of a Factor VII polypeptide from a bulk of a Factor VII polypeptide with respect to desirable glycoforms by fractionated elution from an anion-exchange material with an eluting buffer comprising a certain concentration of calcium ions. The present invention renders it possible to enrich a bulk of a Factor VII polypeptide with respect to desirable glycoforms. | 02-12-2009 |
| 20090041744 | Dimeric and Multimeric FVIIa Compounds - The present invention relates to dimeric or multimeric FVIIa compounds comprising at least two FVIIa polypeptides covalently connected such as to retain the intrinsic catalytic activity of the FVIIa polypeptides. | 02-12-2009 |
| 20090036378 | Use of Factor VIIa or a Tissue Factor Antagonist for Regulating Gene Expression and Cell Migration or Chemotaxis - The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis. | 02-05-2009 |
| 20090018082 | Use of Factor VIIa or Factor VIIa Equivalents for Treating Trauma - The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for treatment of trauma. | 01-15-2009 |
| 20090017557 | FVII Specific Antibodies and Use Thereof - The present invention relates to novel antibodies against FVII, use for determining amount of correctly folded and intact FVII in a sample, as well as for purification and process optimization. | 01-15-2009 |
| 20090011992 | Human Coagulation Factor VII Polypeptides - The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment. | 01-08-2009 |
| 20080318276 | Human Coagulation Factor VII Variants - The invention concerns novel coagulation factor VII variants, wherein the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs; with the proviso that the variant is not FVII(Ala305). | 12-25-2008 |
| 20080305518 | O-Linked Glycoforms Of Polypeptides And Method To Manufacture Them - The present invention relates to compositions comprising glycoproteins having altered patterns of O-linked glycosylation, in particular Factor VII, Factor IX, and methods for making these. | 12-11-2008 |
| 20080274534 | Virus Filtration of Liquid Factor VII Compositions - The present invention relates to a novel method for improving the viral safety of liquid Factor VII compositions, in particular those comprising active Factor VII polypeptides (a Factor VIIa polypeptide). | 11-06-2008 |
| 20080274075 | Poly(Ethylene Glycol) Derivatives and Process For Their Coupling to Proteins - Novel compounds, including PEGylated proteins of the formula, methods for preparing such compounds, methods of using such compounds, and other compositions and methods, are provided. | 11-06-2008 |
| 20080268521 | Purification of Coagulation Factor VII Polypeptides - An improved method for producing FVII and FVIIa polypeptides is disclosed. Also provided are FVII and FVIIa compositions having low contents of auto-degradation products. | 10-30-2008 |
| 20080261886 | Single-Dose Administration of Factor VIIa - The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent. | 10-23-2008 |
| 20080227715 | Liquid composition of factor VII polypeptides - The invention concerns a liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 9.0; (iii) an agent selected from the group consisting of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii) is less than 15 mM; and (iv) An ionic strength modifying agent; wherein the ionic strength of the composition is at least 200 mM. | 09-18-2008 |
| 20080207880 | Reduction of the Content of Protein Contaminents in Compositions Comprising a Vitamin K-Dependent Protein of Interest - The present invention relates to Vitamin K-dependent protein compositions having a very low, or negligible, content of protein contaminants. The present invention also relates to method applicable in the preparation of such Vitamin K-dependent protein compositions. Such methods may either be used alone or in sequential combination with the purpose of reducing the relative content of protein contaminants. The present invention is particularly relevant in the preparation of compositions of coagulation factors selected from Factor X polypeptides (FX/FXa), Factor IX polypeptides (FIX/FIXa), Factor VII polypeptides (FVII/FVIIa), and the anticoagulant Protein C, in particular Factor VII polypeptides. | 08-28-2008 |
| 20080200651 | Selective Reduction and Derivatization of Engineered Proteins Comprising at Least One Non-Native Cysteine - The present invention relates to method for selective reduction and derivatization of recombinantly prepared engineered proteins comprising at least one non-native cysteine, wherein the reduction reaction is conducted in the presence of a redox buffer or in the presence of a triarylphosphine reducing agent. | 08-21-2008 |
